Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.

Abstract: An embodiment of the present invention relates to a therapeutic combination including (a) lacosamide and/or a pharmaceutically acceptable salt thereof; and (b) levetiracetam and/or a pharmaceutically acceptable salt thereof. The combination can be provided in a single dosage form or separate dosage forms.

Abstract: A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.

Abstract: A method for treating pain in painful diabetic neuropathy comprises administering in combination a first agent that comprises a compound as defined herein, illustratively lacosamide, and a second agent effective to provide enhanced treatment of pain, by comparison with the first agent alone. The second agent illustratively comprises an analgesic, an anticonvulsant, an antidepressant or an NMDA receptor antagonist.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.

Abstract: The present invention refers to a method for identifying a modulator of CRMP suitable for the prevention, alleviation or/and treatment of CRMP-associated diseases.

Abstract: The invention relates to novel 6-arylamino-5-cyano-4-pyrimidinones of formula (I) methods for the production thereof, and the use thereof for producing medicaments utilized for improving awareness, concentration, learning capacity, and/or retentiveness of memory. Said compounds (I) show activity as PDE9 inhibitors.

Abstract: The invention relates to novel 6-arylamino-5-cyano-4-pyrimidinones of formula (I) methods for the production thereof, and the use thereof for producing medicaments utilized for improving awareness, concentration, learning capacity, and/or retentiveness of memory. Said compounds (I) show activity as PDE9 inhibitors.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating non-inflammatory musculoskeletal pain or/and non-inflammatory osteoarthritic pain.

Abstract: A method for treating pain, particularly non-inflammatory musculoskeletal pain such as fibromyalgia, myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.

Abstract: A method for treating non-inflammatory musculoskeletal pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to novel 6-arylamino-5-cyano-4-pyrimidinones of formula (I) methods for the production thereof, and the use thereof for producing medicaments utilized for improving awareness, concentration, learning capacity, and/or retentiveness of memory. Said compounds (I) show activity as PDE9 inhibitors.

Abstract: A method for treating non-inflammatory osteoarthritic pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof.

Abstract: A therapeutic combination comprises a first agent comprising a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof, and a second agent effective in combination therewith to (a) provide enhanced treatment of pain associated with or caused by a medical condition, by comparison with the first agent alone; and/or (b) treat another symptom or an underlying cause of the medical condition. The combination can be provided in a single dosage form or separate dosage forms and is illustratively useful for treatment of an arthritic condition and/or pain related thereto.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.

Abstract: The invention relates to novel tetrahydroquinoxalines and processes for their preparation, their use for the treatment and/or the prophylaxis of diseases, in particular for the treatment and/or prophylaxis of states of pain.